The CF33, Vaxinia and Oncarlytics Deal, page-681

Hi All,

Too busy to post extensively today but looking forward to the week ahead given the profound resilience of the US economy, as exemplified by the strong employment figures on Friday evening our time..

I shall post next Sunday but I've made a few notes on what I'm researching which I thought may be of interest to long term holders.

Where are we up to

1. Dose escalation in the Vaxinia Trial - Only one cohort to go in the mono therapy and two in the combination with Keytruda before establishing the optimal Biological dose rate for Vaxinia. Then running through up to the 100 patient participation in the US and Australian hospitals into multiple solid tumour indications

2. PD1 Vaxx - Is now commencing the treatment of naive patients in combination with Roche in addition to advanced stage lung cancer patients Finally Imugene’s vaccines can be trialled on patients prior to surgery and before they have failed on previous treatment arms. Treating patients with comparatively stronger immune systems than advanced late stage lung cancer patients is sure to produce even better clinical trial results than realised in the PD1 Vaxx Phase 1 trial. Keep in mind Imugene CEO and Managing Director Leslie Chong noted this week a patient in the PD1 Vaxx Phase 1 clinical trial is still cancer free after two and a half years.

3. Updated OSR for Her Vaxx Phase 2 - With patients still alive on the Her Vaxx arm of the Phase 2 trial further clinical trial data illustrating an extension in overall survival rates more than 5.9 over and above the standard of care chemotherapy would be well received by the market. Last year in June 2023 initial Overall Survival Rates in the Phase 2 trial were enough to push the IMU share price upwards toward 30 cents.

4. First patient dosed on Oncarlytics - Last year in November when visiting Australia Oncarlytics founder Saul Priceman MD of the City of Hope suggested that when the first in human patients were administered with Oncarlytics that would be a catalyst for Big Pharma to sit up and take notice. The first patient dosed in the forthcoming trial of Oncarlytics is not too far away on the Imugene agenda

5. Check Vacc ongoing details - We are now well over a year and a half into this clinical trial treating late stage Triple Negative Breast Cancer patients at The City Of Hope Cancer Research Facility in the US. With positive signs this far and images of necrosis (i.e ., tumour killing) present in recent CF33 presentations the market is eagerly awaiting further news from founder Professor Yuman Fong on his visit to Australia later this month.

What I’ll be looking out for

1. Potential Nasdaq listing

2. Prospective Asian investor (i.e., as with VLA prior to the takeover)

3. Further activity from IMO probably the same fund manager(s) who pushed IMU down in late 2020 and all the way up in 2021 with the potential to start running it up again now. I guess a closer examination of the share register/broker activity may reveal more throughout June
nb. Clearly they were aware probably they had a month or two following YF’s Sydney Roadshow to accumulate prior to Vaxinia results coming to hand

4. Any movement from Merck

5. Any information surrounding the Her Vaxx Keytruda combination

6. Monil Shah’s speech early next month in Tasmania

7. YF body language and CF33/ Vaxinia analysis at the Sydney Roadshow (and what about those biopsy results)

8. Any more whispers of CR’s in the Vaxinia Trial

9. Roche’s activity

10. Any comment from Amgen re: strategic direction

What I’m envisaging

In June a serious uptick in IMU out of oversold territory off the back of fundamental announcements in the OV trials, an improved macroeconomic economy and biotech index. As outlined above any more hints of CR’s particularly in the Vaxinia combo would be cataclysmic for the SP. Imugene stated in their recent newsletter as a header they were focussing on Vaxinia, I'll leave you with that thought tonight....

Any cancer any time anywhere. Vaxinia.

DYOR Seek investment advice as and when required Opinions only